Research Topic

Longevity & Aging

Aging biology, lifespan extension, hallmarks of aging, and healthspan optimization

2910 articles

Thymosin Beta 4 Cuts Heart Damage After Heart Attacks in Mice and Humans
Longevity & Aging

Thymosin Beta 4 Cuts Heart Damage After Heart Attacks in Mice and Humans

Recombinant human thymosin beta 4 reduces infarct size and cardiac dysfunction via ErbB2 signaling in both animal models and a clinical trial.

Research Paper
May 19, 2026 0
Thymosin Beta 4 Reverses Alzheimer's Pathology in Human Brain Organoids and Mice
Longevity & Aging

Thymosin Beta 4 Reverses Alzheimer's Pathology in Human Brain Organoids and Mice

Scientists identify Tβ4 as a neuroprotective factor that rescues neuronal loss and amyloid buildup in both human fAD organoids and 5xFAD mice.

Research Paper
May 19, 2026 0
FDA Opens Drug Repurposing Push to Tackle Chronic and Rare Disease Gaps
Longevity & Aging

FDA Opens Drug Repurposing Push to Tackle Chronic and Rare Disease Gaps

The FDA is seeking public input on repurposing approved drugs for new uses, targeting metabolic, neurodegenerative, and rare diseases.

Press Release
May 19, 2026 0
FDA Approves Enhertu for Early-Stage HER2+ Breast Cancer in Curative Settings
Longevity & Aging

FDA Approves Enhertu for Early-Stage HER2+ Breast Cancer in Curative Settings

Trastuzumab deruxtecan wins two new FDA approvals for early HER2+ breast cancer, showing dramatic survival gains over standard therapy.

Press Release
May 19, 2026 0
Darolutamide Plus ADT Cuts Prostate Cancer Progression Risk by 71% in US Trial
Longevity & Aging

Darolutamide Plus ADT Cuts Prostate Cancer Progression Risk by 71% in US Trial

A US phase II trial confirms darolutamide combined with ADT dramatically improves survival in metastatic hormone-sensitive prostate cancer.

Press Release
May 19, 2026 0
FDA Approves First-in-Class Blood Pressure Pill That Targets Aldosterone at the Source
Longevity & Aging

FDA Approves First-in-Class Blood Pressure Pill That Targets Aldosterone at the Source

Baxdrostat blocks aldosterone production directly, cutting systolic BP by ~15 mmHg in resistant hypertension patients who failed other drugs.

Press Release
May 19, 2026 0
Erectile Dysfunction Linked to Significantly Higher Substance Abuse Risk in Older Men
Longevity & Aging

Erectile Dysfunction Linked to Significantly Higher Substance Abuse Risk in Older Men

A large retrospective study finds older men with ED face 2x higher sedative abuse risk and 50%+ greater opioid and cocaine risk.

Press Release
May 19, 2026 0
Daily Grape Consumption Rewires Skin Genes to Shield Against UV Damage
Longevity & Aging

Daily Grape Consumption Rewires Skin Genes to Shield Against UV Damage

New research finds eating grapes daily for two weeks alters skin gene expression, boosting UV protection and cutting oxidative stress markers.

Press Release
May 19, 2026 0
New mRNA Drug REP-0004 Targets Liver to Rapidly Reverse Heart Disease and Atherosclerosis
Longevity & Aging

New mRNA Drug REP-0004 Targets Liver to Rapidly Reverse Heart Disease and Atherosclerosis

Repair Biotechnologies' REP-0004 uses mRNA-lipid nanoparticles to clear toxic free cholesterol from the liver, reversing plaque and liver disease.

Press Release
May 19, 2026 0
One-Shot GLP-1 Gene Therapy Heads to EU Trials as Weight Loss Drugs Race Forward
Longevity & Aging

One-Shot GLP-1 Gene Therapy Heads to EU Trials as Weight Loss Drugs Race Forward

Fractyl Health's RJVA-001 aims to trigger lasting GLP-1 production from a single dose, as oral and multi-action obesity drugs also advance rapidly.

Press Release
May 19, 2026 0
New Digital Tool Detects Memory Decline Years Before Symptoms Appear
Longevity & Aging

New Digital Tool Detects Memory Decline Years Before Symptoms Appear

Cambridge-backed PREMAZ measures memory precision to catch Alzheimer's warning signs far earlier than standard cognitive tests.

Press Release
May 19, 2026 0
RNA Drug Cuts Liver Fat by 46% in Genetic MASH Patients in Phase 1 Trial
Longevity & Aging

RNA Drug Cuts Liver Fat by 46% in Genetic MASH Patients in Phase 1 Trial

A targeted RNA interference therapy slashed liver fat nearly in half in 12 weeks for patients with a common genetic variant tied to fatty liver disease.

Press Release
May 19, 2026 0
PreviousPage 10 of 243Next